2022-501910-79-01RecruitingPhase 1/2
A study of niraparib in combination with abemaciclib for late line treatment of ovarian cancer: a single center, open label, single arm, phase Ib/II trial (NICHOL TRIAL)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 25 Jun 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 73 (estimated)
- First submitted
- 15 Feb 2024
- Start date
- 18 Sept 2024
- Lead sponsor
- Fondazione IRCCS Istituto Nazionale Dei Tumori
- Diseases
- Ovarian cancer
- EU CT number
- 2022-501910-79-01
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 73
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione IRCCS - Istituto Nazionale dei Tumori | Milan | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.